title: Therapeutic drug monitoring, mucosal healing, deep remission: the path to nirvana in Crohn's disease?
authors.affiliation: Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, Massachusetts.
authors.forename: Alan C
authors.initials: AC
authors.lastname: Moss
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood* / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000097:blood* / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000097:blood* / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068879:Adalimumab; D000068582:Certolizumab Pegol